Guyasuta Investment Advisors Inc. lowered its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 11.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,110 shares of the biopharmaceutical company’s stock after selling 4,020 shares during the period. Guyasuta Investment Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $1,869,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in BMY. CSat Investment Advisory L.P. bought a new stake in Bristol-Myers Squibb in the second quarter valued at $113,000. Cypress Capital Management LLC WY boosted its holdings in shares of Bristol-Myers Squibb by 154.7% during the 3rd quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,160 shares in the last quarter. Landaas & Co. WI ADV bought a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at $131,000. Selective Wealth Management bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at $184,000. Finally, LFA Lugano Financial Advisors SA boosted its holdings in shares of Bristol-Myers Squibb by 85.8% during the 3rd quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 1,481 shares in the last quarter. Institutional investors and hedge funds own 72.60% of the company’s stock.
BMY opened at $54.07 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $88.25 billion, a PE ratio of 17.96, a P/E/G ratio of 1.51 and a beta of 1.08. Bristol-Myers Squibb Co has a 1 year low of $46.94 and a 1 year high of $70.05.
The business also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Stockholders of record on Friday, October 5th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.96%. The ex-dividend date was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.
BMY has been the topic of a number of research reports. Barclays boosted their target price on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Friday, October 12th. Morgan Stanley dropped their target price on shares of Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, November 6th. Credit Suisse Group set a $61.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, October 14th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a report on Friday, October 5th. Finally, ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Friday, October 19th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $61.84.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Further Reading: Candlestick
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.